GlassScriptPhysician profile
Shannon C Gilham
NPI 1508074931
$3,604.74
in general payments reported to CMS, 2019-2025
28 companies · $441 in 2025
The $441 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $220 · 2021: $190 · 2022: $267 · 2023: $350 · 2024: $1,505 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268 · Travel and Lodging: $928 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.30 |
| Travel and Lodging | $928.45 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,119.96 | 2024 | |
| Abbvie INC. | $443.68 | 2019-2025 | |
| Astellas Pharma US INC | $278.81 | 2019-2025 | Veozah, Myrbetriq |
| Organon LLC | $160.91 | 2022-2025 | Nexplanon, Jada System |
| Amgen INC. | $158.02 | 2019-2023 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $146.63 | 2021-2025 | |
| Hologic Sales and Service, LLC | $137.41 | 2019-2024 | Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $130.15 | 2019 | |
| Sumitomo Pharma America, INC. | $123.80 | 2023-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $109.11 | 2021-2025 | |
| Exact Sciences Corporation | $92.83 | 2024-2025 | Cologuard Collection Kit |
| Scynexis, INC. | $86.61 | 2022 | |
| Applied Medical Resources Corporation | $81.75 | 2020 | |
| Lupin INC. | $73.31 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $73.25 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $71.34 | 2021-2024 | Axonics, Bulkamid |
| Exeltis, USA INC. | $67.61 | 2024-2025 | Slynd, Twirla |
| Mylan Pharmaceuticals INC. | $43.33 | 2019-2021 | |
| Ethicon US, LLC | $29.11 | 2019 | |
| Coopersurgical, INC. | $24.52 | 2020-2021 | |
| Pfizer INC. | $23.86 | 2025 | |
| Merck Sharp & Dohme LLC | $23.45 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.25 | 2019 | |
| Allergan, INC. | $20.25 | 2019 | |
| Medtronic, INC. | $18.47 | 2022 | |
| Sanofi Pasteur INC. | $17.66 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.56 | 2021 | |
| Evofem Biosciences, INC. | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Gilham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.